Muscular Diseases Clinical Trial
Official title:
Observational Study Into the Effect on Muscle Wasting and Multiple Organ Function of Ischaemia-reperfusion Injury After Major Aortic Surgery
Single-centre observational study over one year investigating the mechanisms of muscle homeostasis in patients with acute skeletal muscle atrophy following major aortic surgery
Some patients who are critically ill develop a syndrome of muscle weakness called Intensive
Care Unit Acquired Paresis. This syndrome involves the development of severe muscle wasting
and weakness and affects all skeletal muscles including the muscles which help one breathe.
Muscle wasting and weakness whilst critically ill cause prolongation of mechanical
ventilation, longer stays on the ICU, reduced mobility and prolonged rehabilitation in
survivors. It has also been shown to increase the risk of death on ICU, due to an inability
to wean patients from mechanical ventilation. Most patients recover; however in some, the
effects last for many years and patients may not recover fully.
Although there is some understanding of why this syndrome develops, the molecular processes
underlying the muscle wasting are not well understood. From the current scientific evidence,
the investigators have identified a group or family of proteins believed to be important in
the development of this condition, the activity of which are regulated by disease processes
thought to lead to Intensive Care Unit Acquired Paresis (e.g. infection, inflammation,
oxidative stress, immobility).
This research aims to investigate the role of these proteins in human tissue from patients
who are at risk of Intensive Care Unit Acquired paresis. Even patients who do not go on to
develop the full syndrome, in the early stages of ICU care, show some signs of muscle changes
and loss of strength.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00199745 -
Differences in Atorvastatin Metabolite Ratios as a Diagnostic Tool in Detecting Atorvastatin Induced Myotoxicity
|
Phase 4 | |
| Completed |
NCT03979157 -
Non-invasive Molecular Imaging of Muscle Structure (MSOT_muscles)
|
N/A | |
| Completed |
NCT04115475 -
New Imaging Biomarkers for Muscular Diseases - Multispectral Optoacoustic Imaging in Spinal Muscular Atrophy
|
N/A | |
| Completed |
NCT03440034 -
Study of Pioglitazone in Sporadic Inclusion Body Myositis
|
Phase 1 | |
| Completed |
NCT04838509 -
Diagnoses Associated With Persistent Elevation of Creatine Kinase
|
||
| Completed |
NCT03406780 -
A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
|
Phase 2 | |
| Completed |
NCT01826487 -
Phase 3 Study of Ataluren in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)
|
Phase 3 | |
| Terminated |
NCT02090959 -
An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation Dystrophinopathy
|
Phase 3 | |
| Recruiting |
NCT05126758 -
A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
|
Phase 3 | |
| Recruiting |
NCT05183152 -
Non-invasive BCI-controlled Assistive Devices
|
N/A | |
| Completed |
NCT03179631 -
Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy
|
Phase 3 | |
| Terminated |
NCT02829814 -
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
|
Phase 3 | |
| Recruiting |
NCT06226376 -
Mollii Suit and Fibromyalgia (EXOFIB 2)
|
N/A | |
| Completed |
NCT03250988 -
Prevalence of Comorbid Spasticity and Urinary Incontinence in Residents of a Long-Term Care Facility
|
||
| Completed |
NCT03209960 -
Validity and Inter-Rater Reliability of a Novel Bedside Referral Tool for Spasticity
|
||
| Completed |
NCT03211390 -
Using Telemedicine to Improve Spasticity Diagnosis Rates
|
||
| Completed |
NCT00609063 -
The Effect of Statin Medications on Muscle Performance (The STOMP Study)
|
N/A | |
| Terminated |
NCT00240981 -
TOM: Testosterone in Older Men With Sarcopenia
|
Phase 4 | |
| Completed |
NCT03268421 -
Fibromyalgia Integrative Training for Adolescents With Juvenile Fibromyalgia
|
N/A | |
| Completed |
NCT05730842 -
Absorption, Metabolism, Excretion and Absolute Bioavailability of EDG-5506 in Healthy Volunteers
|
Phase 1 |